Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Exomic microRNA Profiling of Bone Marrow Aspirate Plasma and Comparison with mRNA Profiles Used in the Clinical Management of Multiple Myeloma

Ryan K Van Laar, PhD, Rachel Flinchum, MSc, Brown Nathan, MSc, Joseph Ramsey, MSc, John Shaughnessy, PhD, Joshua Epstein, PhD, Christoph Heuck, MD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 5681.

https://doi.org/10.1182/blood.V124.21.5681.5681

Published: 2014

Journal Articles

Consequences of Intermittent PTH Treatment on Myeloma Growth, Bone Disease and Molecular Profiling of Whole Myelomatous Bone

Angela Pennisi, MD, Xin Li, PhD, Bart Barlogie, M.D., Ph.D., John Shaughnessy PhD, Jr., Shmuel Yaccoby, PhD

Blood (2010) 116 (21): 4063.

https://doi.org/10.1182/blood.V116.21.4063.4063

Published: 2010

Journal Articles

Glucocorticoid Receptor Expression Correlates with Clinical Outcome in Myeloma Patients Treated with Glucocorticoid-Containing Regimens.

Shuo Ma, MD, PhD, Fenghuang Zhan, MD, PhD, Chunguang Ma, Michael Tessel, Lijun Zhang, S. Vincent Rajkumar, MD, Seema Singhal, Bart Barlogie, MD, John Shaughnessy, PhD, Steven T. Rosen, MD, Nancy Krett, PhD

Blood (2008) 112 (11): 1700.

https://doi.org/10.1182/blood.V112.11.1700.1700

Published: 2008

Journal Articles

Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.

Angela Pennisi, MD, Xin Li, PhD, Maurizio Zangari, MD, Jeffrey R. Sawyer, MD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD, Shmuel Yaccoby, PhD

Blood (2007) 110 (11): 548.

https://doi.org/10.1182/blood.V110.11.548.548

Published: 2007

Journal Articles

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Bart Barlogie, MD, PhD, Yongsheng Huang, PhD, Jeffrey Sawyer, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 114.

https://doi.org/10.1182/blood.V108.11.114.114

Published: 2006

Journal Articles

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Ronald Walker, MD, John Shaughnessy, PhD, Jeffery Haessler, MS, Joshua Epstein, DSc, Jeffery Sawyer, PhD, Elias J. Anaissie, MD, Frits Van Rhee, MD PhD, Guido Tricot, MD PhD, Maurizio Zangari, MD, Mauricio Pineda-Roman, MD, Klaus Hollmig, MD, John Crowley, MD, Bart Barlogie, MD PhD

Blood (2006) 108 (11): 3515.

https://doi.org/10.1182/blood.V108.11.3515.3515

Published: 2006

Journal Articles

DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation.

Guido Tricot, MD, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, PhD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 3392.

https://doi.org/10.1182/blood.V108.11.3392.3392

Published: 2006

Journal Articles

Atacicept (TACI-Ig) Inhibits Growth of TACI high Primary Myeloma Cells in SCID-Hu Mice.

Shmuel Yaccoby, PhD, Stacey R. Dillon, PhD, Wen Ling, Paul Perkins, John R. Tisdale, Angela Pennisi, MD, Rinku Saha, Xin Li, PhD, Bart Barlogie, MD, PhD, Guido Tricot, MD, Fenghuang Zhan, MD, PhD, John Shaughnessy, PhD

Blood (2006) 108 (11): 842.

https://doi.org/10.1182/blood.V108.11.842.842

Published: 2006

Journal Articles

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Federica Cavallo, MD, Laurie Jones-Jackson, MD, Elias Anaissie, MD, Terri Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 3493.

https://doi.org/10.1182/blood.V106.11.3493.3493

Published: 2005

Journal Articles

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

Selina Chen-Kiang, PhD, Scott Ely, MD, MPH, Maurizio Di Liberto, PhD, Kaida Wu, PhD, John Shaughnessy, PhD, Malcolm Moore, DPhil, Ruben Niesvizky, MD, Eunice Hatada, PhD

Blood (2005) 106 (11): 1564.

https://doi.org/10.1182/blood.V106.11.1564.1564

Published: 2005

Journal Articles

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Ichiro Hanamura, MD, Peter Stewart, PhD, Frederica Cavallo, MD, Bart Burington, MS, Erik Rasmussen, MS, John Crowley, PhD, Fenghuang Zhan, MD, PhD, Yongsheng Huang, MS, Bart Barlogie, MD, PhD, John Shaughnessy, PhD

Blood (2005) 106 (11): 1553.

https://doi.org/10.1182/blood.V106.11.1553.1553

Published: 2005

Journal Articles

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Ronald Walker, MD, Erik Rasmussen, MS, Laurie Jones-Jackson, MD, Elias J. Anaissie, MD, Terri L. Alpe, BS, Joshua Epstein, DSc, Frits Van Rhee, MD, PhD, Maurizio Zangari, MD, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD.

Blood (2005) 106 (11): 5079.

https://doi.org/10.1182/blood.V106.11.5079.5079

Published: 2005

Journal Articles

Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response.

Ronald Walker, MD, L. Jones-Jackson, Eric Rasmussen, M. Miceli, Elias Anaissie, MD, Joshua Epstein, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 758.

https://doi.org/10.1182/blood.V104.11.758.758

Published: 2004

Journal Articles

The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features.

Fenghuang Zhan, PhD, Bart Barlogie, MD, PhD, Yongsheng Huang, PhD, Eric Rasmussen, Jeffrey Sawyer, M. Santra, Ronald Walker, MD, Guido Tricot, MD, PhD, John Crowley, Elias Anaissie, MD, John Shaughnessy, PhD

Blood (2004) 104 (11): 76.

https://doi.org/10.1182/blood.V104.11.76.76

Published: 2004

Journal Articles

Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells.

Yun Ge, PhD, Fenghuang Zhan, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, Guido Tricot, MD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD

Blood (2004) 104 (11): 634.

https://doi.org/10.1182/blood.V104.11.634.634

Published: 2004

Journal Articles

High Frequency of Molecular Remissions (m-CR) in Multiple Myeloma Patients Achieving a Hematologic Complete Remission (CR) on Total Therapy II (TT-2).

Guido Tricot, MD, PhD, Matteo Carrabba, MD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, John Shaughnessy, PhD, Paolo Corradini, MD

Blood (2004) 104 (11): 933.

https://doi.org/10.1182/blood.V104.11.933.933

Published: 2004

Journal Articles

Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III.

Ronald Walker, MD, L. Jones-Jackson, Eric Rasmussen, M. Miceli, Elias Anaissie, MD, Joshua Epstein, Guido Tricot, MD, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 941.

https://doi.org/10.1182/blood.V104.11.941.941

Published: 2004

Journal Articles

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Blood (2004) 104 (11): 784.

https://doi.org/10.1182/blood.V104.11.784.784

Published: 2004

Journal Articles

Soluble and Membrane Bound MICA in Myeloma Do Not Adversely Effect Regulation of Natural Killer Cell Function Via NKG2D..

Jumei Shi, MD, PhD, Susann Szmania, BS, Fenghuang Zhan, PhD, John Shaughnessy, PhD, Bart Barlogie, MD, PhD, Guido Tricot, MD, PhD, Frits van Rhee, MD, PhD

Blood (2004) 104 (11): 2462.

https://doi.org/10.1182/blood.V104.11.2462.2462

Published: 2004

Journal Articles

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

Frits van Rhee, MD, PhD, Susann M. Szmania, BS, Mindy Pomtree, Frank Zhan, Amberly Moreno, BS, Nancy Rosen, Michele Fox, MD, Bart Barlogie, MD, PhD, John Shaughnessy, PhD, Ramesh Batchu, PhD, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 2464.

https://doi.org/10.1182/blood.V104.11.2464.2464

Published: 2004

NARROW

Exomic microRNA Profiling of Bone Marrow Aspirate Plasma and Comparison with mRNA Profiles Used in the Clinical Management of Multiple Myeloma

Consequences of Intermittent PTH Treatment on Myeloma Growth, Bone Disease and Molecular Profiling of Whole Myelomatous Bone

Glucocorticoid Receptor Expression Correlates with Clinical Outcome in Myeloma Patients Treated with Glucocorticoid-Containing Regimens.

Exploitation of Novel Hyperdiploid and Nonhyperdiploid Myeloma Cell Lines for Studying Innovative Interventions for Myeloma and Its Associated Bone Disease.

Metaphase Cytogenetics Adds to Gene Expression Profiling in the Identification of High Risk Multiple Myeloma.

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

DNA Repair Genes Are Upregulated in Multiple Myeloma (MM) Patients Relapsing after Tandem Transplantation.

Atacicept (TACI-Ig) Inhibits Growth of TACI high Primary Myeloma Cells in SCID-Hu Mice.

Correlation of Suppression of FDG PET Uptake with Serum Free Light Chain Levels - Both FDG PET-CT and Serum Clonal Free Light Chain Response Precede and Predict the Likelihood of Subsequent Complete Remission in Newly Diagnosed Multiple Myeloma.

Aberrant Autocrine and Paracrine CD40L Signaling Promotes Primary Myeloma Cell Survival and Attenuates Bortezomib-Induced Apoptosis.

Frequent Gains of Chromosome Arm 1q21 in Plasma Cell Dyscrasia Detected by Fluorescence In Situ Hybridization: Incidence Increases from MGUS to Relapsed Myeloma and Is Related to Disease Progression and Prognosis.

Investigation of Discrepancies between Baseline MRI and PET-CT Studies in Patients with Newly Diagnosed Multiple Myeloma.

Diagnostic Imaging of Multiple Myeloma - FDG PET and MRI Complementary for Tracking Short Vs. Long Term Tumor Response.

The Transcriptome of Multiple Myeloma (MM) Defines Disease Subgroups with Distinct Genetic and Clinical Features.

Fibroblast Activation Protein (FAP) Is a Critical Microenvironmental Survival Factor for Myeloma Plasma Cells.

High Frequency of Molecular Remissions (m-CR) in Multiple Myeloma Patients Achieving a Hematologic Complete Remission (CR) on Total Therapy II (TT-2).

Rapid Response to Treatment of Multiple Myeloma Detected with FDG PET Scanning in Multiple Myeloma - Early Results from Total Therapy III.

Serial Gene Expression Studies of Malignant Plasma Cells before Treatment and after Relapse: Identifying Genes Linked to Drug Resistance in Myeloma.

Soluble and Membrane Bound MICA in Myeloma Do Not Adversely Effect Regulation of Natural Killer Cell Function Via NKG2D..

NY-ESO-1 Specific Antibodies Are Frequently Detected in Hight-Risk Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only